Intervention Protocol

Adverse gastrointestinal effects of COX-2 Inhibitors for inflammatory diseases

  1. Alaa Rostom1,*,
  2. Catherine Dube2,
  3. Emilie Jolicoeur3,
  4. Janet L. Joyce4,
  5. Katherine Muir5

Editorial Group: Cochrane Upper Gastrointestinal and Pancreatic Diseases Group

Published Online: 21 JAN 2009

DOI: 10.1002/14651858.CD004519

Database Title

Additional Information

How to Cite

Rostom A, Dube C, Jolicoeur E, Joyce JL, Muir K. Adverse gastrointestinal effects of COX-2 Inhibitors for inflammatory diseases (Protocol). Cochrane Database of Systematic Reviews 2003, Issue 4. Art. No.: CD004519. DOI: 10.1002/14651858.CD004519.

Author Information

  1. 1

    Foothills Medical Centre, University of Calgary Department of Medicine / Gastroenterology, Calgary, Alberta, Canada

  2. 2

    Ottawa Hospital - Civic Campus, University of Ottawa - Department of Medicine, Ottawa, Ontario, Canada

  3. 3

    A-1 Endoscopy Unit, Division of Gastroenterology, Ottawa, Ontario, Canada

  4. 4

    Canadian Cochrane Network and Centre, Ottawa, Ontario, Canada

  5. 5

    Ottawa Health and Research Institute, Gastroenterology, Ottawa, Ontario, Canada

*Alaa Rostom, University of Calgary Department of Medicine / Gastroenterology, Foothills Medical Centre, 1403 - 29 St. N.W, Calgary, Alberta, T2N 2T9, Canada. alrostom@ucalgary.ca.

Publication History

  1. Publication Status: Edited (no change to conclusions)
  2. Published Online: 21 JAN 2009

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (125K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

The primary objective of this systematic review is to compare the upper GI safety of currently available COX-2 inhibitors with that of non-selective NSAIDs (with or without the concomitant use of gastroprotective agents) and with that of placebo. The review will also consider the upper GI safety of COX-2 inhibitors compared to other COX-2 inhibitors.

Specifically the review aims to address the following questions:

  • As a group do the COX-2 inhibitors have less GI toxicity than standard NSAIDs overall?
  • Do the various COX-2 inhibitors have different degrees of GI toxicities? And therefore do certain standard NSAIDs have GI safety profiles that are similar to certain COX-2 inhibitors?
  • Does the use of a standard NSAID in combination with a gastroprotective agent (e.g. a proton pump inhibitor) offer similar or greater GI safety than COX-2 inhibitors used when used alone?

View Full Article (HTML) Full (125K)